Patent · US Active

Antibodies to CLL-1

US8536310B2 · kind B2 · utility

9Cited by

0References

10Claims

0Family size

Assignee

ARCA Biopharma, Inc. · US

Inventors

Arie Abo · Oakland, US
Wouter Korver · South San Francisco, US

Key dates

Filing date	Oct 3, 2008
Grant date	Sep 17, 2013
Priority date	—
Expiry date	Jan 23, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/21
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.